What cancers and diseases are specifically indicated for Sorafenib/Nexavar?

Sorafenib/Nexavar (Sorafenib), as a multi-target tyrosine kinase inhibitor, is mainly used to treat a variety of malignant tumors, especially hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and certain types of thyroid cancer. Its unique pharmacological mechanism makes it highly effective in the treatment of these tumors, especially in patients with advanced tumors who are inoperable or have metastasized.

First, sorafenib is one of the standard treatments for patients with hepatocellular carcinoma (HCC), especially those who cannot undergo surgery. By inhibiting tumor angiogenesis and preventing the growth of cancer cells, it can significantly delay the progression of liver cancer and improve patients' survival and quality of life. In patients with advanced liver cancer, sorafenib can delay the progression of the disease and reduce the rate of tumor spread, and is often used in combination with other supportive therapies.

Secondly, sorafenib is also widely used to treat metastatic renal cell carcinoma (mRCC). This type of cancer is often difficult to treat. As a targeted drug, sorafenib helps slow down the progression of the disease and prolong survival by inhibiting the growth of cancer cells and tumor angiogenesis. Sorafenib is often used as a first-line treatment option in patients with kidney cancer, especially for those who are inoperable, providing an effective treatment.

In addition, sorafenib is approved for the treatment of metastatic thyroid cancer (DTC), particularly in patients who have not responded to iodine-131 therapy. By inhibiting the proliferation of thyroid cancer cells, sorafenib can effectively slow down the progression of thyroid cancer, especially in advanced disease. For other types of malignant tumors, such as colorectal cancer, sorafenib has also shown certain efficacy in some clinical trials, but it has not yet been widely used as a standard treatment option.

Reference materials:https://www.nexavar.com/